BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
-7.42%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$5.38B
AUM Growth
+$5.38B
(-8.2%)
Cap. Flow
+$102M
Cap. Flow
% of AUM
1.9%
Top 10 Holdings %
Top 10 Hldgs %
41.73%
Holding
223
New
22
Increased
133
Reduced
36
Closed
13
Top Buys
| 1 |
Ionis Pharmaceuticals
IONS
|
$21.9M |
| 2 |
Glaukos
GKOS
|
$18.4M |
| 3 |
Arvinas
ARVN
|
$17.4M |
| 4 |
Agios Pharmaceuticals
AGIO
|
$14.4M |
| 5 |
Becton Dickinson
BDX
|
$12.9M |
Top Sells
| 1 |
CELG
Celgene Corp
CELG
|
$75.9M |
| 2 |
Gilead Sciences
GILD
|
$32.8M |
| 3 |
Neurocrine Biosciences
NBIX
|
$22.3M |
| 4 |
Teladoc Health
TDOC
|
$20M |
| 5 |
AVDR
Avedro, Inc Common Stock
AVDR
|
$15.8M |
Sector Composition
| 1 | Healthcare | 94.28% |
| 2 | Industrials | 0.53% |
| 3 | Technology | 0.51% |
| 4 | Financials | 0.07% |
| 5 | Consumer Discretionary | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
CVS Health
CVS
$92.8B
| $6.67M | 0.12% | 105,688 +46,362 | +78% | +$2.92M |
|
|
VCRA
102
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
| $6.14M | 0.11% | 249,173 +55,539 | +29% | +$1.37M |
|
103
Guardant Health
GH
$8.41B
| $6.05M | 0.11% | 94,761 -25,087 | -21% | -$1.6M |
|
|
QTNT
104
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $5.81M | 0.11% | 747,894 +14,453 | +2% | +$112K |
|
105
Viatris
VTRS
$12.3B
| $5.8M | 0.11% | +293,200 | New | +$5.8M |
|
106
Inogen
INGN
$216M
| $5.43M | 0.1% | 113,323 +16,480 | +17% | +$790K |
|
107
Phreesia
PHR
$1.88B
| $5.35M | 0.1% | +220,690 | New | +$5.35M |
|
|
AGN
108
DELISTED
Allergan plc
AGN
| $5.18M | 0.1% | 30,800 -1,300 | -4% | -$219K |
|
109
Health Catalyst
HCAT
$239M
| $5.07M | 0.09% | +160,216 | New | +$5.07M |
|
110
10x Genomics
TXG
$1.74B
| $5.04M | 0.09% | +100,000 | New | +$5.04M |
|
|
SDC
111
DELISTED
SmileDirectClub, Inc. Class A Common Stock
SDC
| $4.86M | 0.09% | +350,000 | New | +$4.86M |
|
112
Cidara Therapeutics
CDTX
$1.66B
| $4.58M | 0.09% | 2,295,272 | – | – |
|
|
MTLS
113
Materialise
MTLS
$302M
| $4.45M | 0.08% | 240,770 | – | – |
|
|
SILK
114
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $4.29M | 0.08% | 131,954 +5,144 | +4% | +$167K |
|
115
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $4.08M | 0.08% | 201,435 +34,800 | +21% | +$705K |
|
116
Henry Schein
HSIC
$8.44B
| $4.04M | 0.08% | 63,575 +5,658 | +10% | +$359K |
|
117
Kezar Life Sciences
KZR
$28.9M
| $4.04M | 0.08% | 1,230,523 | – | – |
|
118
Penumbra
PEN
$10.6B
| $3.37M | 0.06% | 25,048 -132 | -0.5% | -$17.8K |
|
|
SYNH
119
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $3.3M | 0.06% | 62,000 | – | – |
|
120
Acadia Pharmaceuticals
ACAD
$4.38B
| $3.25M | 0.06% | 90,400 -13,400 | -13% | -$482K |
|
|
SWAV
121
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $3.03M | 0.06% | 101,358 +3,811 | +4% | +$114K |
|
122
Avantor
AVTR
$9.18B
| $2.9M | 0.05% | 196,951 +9,720 | +5% | +$143K |
|
123
PTC Therapeutics
PTCT
$3.92B
| $2.75M | 0.05% | 81,200 -2,300 | -3% | -$77.8K |
|
124
Neuronetics
STIM
$220M
| $2.71M | 0.05% | 325,961 +1,182 | +0.4% | +$9.82K |
|
125
Kura Oncology
KURA
$686M
| $2.52M | 0.05% | 166,300 +21,100 | +15% | +$320K |
|